UY26935A1 - Sales de monoamina y diamina orgánica, sales de monoaminoácido y diaminoácido, y sales de éster de monoaminoácido y diaminoácido de precusor de fosfato de combretastatina a-4 campo de la invención - Google Patents

Sales de monoamina y diamina orgánica, sales de monoaminoácido y diaminoácido, y sales de éster de monoaminoácido y diaminoácido de precusor de fosfato de combretastatina a-4 campo de la invención

Info

Publication number
UY26935A1
UY26935A1 UY26935A UY26935A UY26935A1 UY 26935 A1 UY26935 A1 UY 26935A1 UY 26935 A UY26935 A UY 26935A UY 26935 A UY26935 A UY 26935A UY 26935 A1 UY26935 A1 UY 26935A1
Authority
UY
Uruguay
Prior art keywords
salts
acid
monoamino
diamino
preferrant
Prior art date
Application number
UY26935A
Other languages
English (en)
Inventor
John J Venit
Yande Huang
Mandar V Dali
Charles E Dahlheim
Manisha M Dali
Ravindra W Tejwani
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26935A1 publication Critical patent/UY26935A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona en la presente sales de precursor de combretastatina A-4 novedosos y útiles que incrementan la solubilidad de combretastatina A-4, regeneran fácilmente combretastatina A-4 in vivo bajo condiciones fisiológicas normales y los cuales producen productos fisiológicamente tolerables como un resultado de la regeneración de combretastatina A-4.
UY26935A 2000-09-14 2001-09-13 Sales de monoamina y diamina orgánica, sales de monoaminoácido y diaminoácido, y sales de éster de monoaminoácido y diaminoácido de precusor de fosfato de combretastatina a-4 campo de la invención UY26935A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23256800P 2000-09-14 2000-09-14
US25192100P 2000-12-07 2000-12-07

Publications (1)

Publication Number Publication Date
UY26935A1 true UY26935A1 (es) 2002-04-26

Family

ID=26926130

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26935A UY26935A1 (es) 2000-09-14 2001-09-13 Sales de monoamina y diamina orgánica, sales de monoaminoácido y diaminoácido, y sales de éster de monoaminoácido y diaminoácido de precusor de fosfato de combretastatina a-4 campo de la invención

Country Status (26)

Country Link
US (2) US6670344B2 (es)
EP (1) EP1320534B1 (es)
JP (2) JP4149804B2 (es)
KR (1) KR100858464B1 (es)
CN (1) CN100338077C (es)
AR (1) AR030727A1 (es)
AT (1) ATE293630T1 (es)
AU (2) AU785183B2 (es)
BR (1) BRPI0107210B1 (es)
CA (1) CA2422359C (es)
DE (1) DE60110249T2 (es)
EE (1) EE200200249A (es)
ES (1) ES2241872T3 (es)
HK (1) HK1052356B (es)
HU (1) HU229055B1 (es)
IL (3) IL149601A0 (es)
MX (1) MXPA03002209A (es)
NO (1) NO329973B1 (es)
NZ (1) NZ524926A (es)
PE (1) PE20020445A1 (es)
PT (1) PT1320534E (es)
RS (1) RS50309B (es)
SK (1) SK287117B6 (es)
TW (1) TWI250163B (es)
UY (1) UY26935A1 (es)
WO (1) WO2002022626A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019944D0 (en) * 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US7603190B2 (en) * 2001-04-19 2009-10-13 Sony Corporation Digital recording/reproducing apparatus
JP2004536847A (ja) * 2001-07-13 2004-12-09 オキシジーン， インコーポレイテッド 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
CN100365000C (zh) * 2003-09-18 2008-01-30 雍智全 Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用
CN100579532C (zh) 2003-12-23 2010-01-13 先灵-普劳有限公司 具有改善水溶性的氟苯尼考前药
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
JP2009521424A (ja) * 2005-12-19 2009-06-04 メチルジーン インコーポレイテッド 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤
CN101460154B (zh) 2006-04-04 2015-07-01 Kg艾克维泽生公司 包含抗血小板剂和抑酸剂的口服剂型
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008103415A2 (en) * 2007-02-22 2008-08-28 Oxigene, Inc. Methods of preparing phosphoric acids of combretastatin and derivatives thereof
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
ES2449074T3 (es) * 2007-06-22 2014-03-18 Bristol-Myers Squibb Holdings Ireland Composiciones en forma de comprimidos que contienen atazanavir
MX2009013499A (es) * 2007-06-22 2010-01-18 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
KR20100033378A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
ATE503467T1 (de) * 2007-06-22 2011-04-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
SI2219451T1 (sl) 2007-11-21 2015-02-27 Oxigene, Inc. Postopek za zdravljenje hematopoetskih neoplazem
CN102757338B (zh) * 2012-02-29 2015-02-25 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2017031157A1 (en) 2015-08-18 2017-02-23 Mateon Therapeutics, Inc. Use of vdas to enhance immunomodulating therapies against tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
DE3438386A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Phosphorsaeurevinylbenzylester, ihre herstellung und verwendung
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
DE19506885A1 (de) 1995-02-17 1996-08-22 Schering Ag Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999035159A1 (en) * 1998-01-08 1999-07-15 Brigham & Women's Hospital, Inc. Lymphoma/leukemia oncogene, oncoprotein and methods of use
ATE476436T1 (de) * 1998-01-09 2010-08-15 Univ Arizona Synthese von combretastatin a-4 prodrugs
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
ES2241872T3 (es) 2005-11-01
HK1052356B (zh) 2008-06-27
JP4149804B2 (ja) 2008-09-17
AU2007200218A1 (en) 2007-02-08
IL149601A (en) 2007-06-17
JP2004509128A (ja) 2004-03-25
BR0107210A (pt) 2003-02-25
PE20020445A1 (es) 2002-05-18
DE60110249D1 (de) 2005-05-25
IL176088A0 (en) 2006-10-05
AU785183B2 (en) 2006-10-19
CA2422359C (en) 2008-12-23
BRPI0107210B1 (pt) 2017-09-26
KR100858464B1 (ko) 2008-09-16
WO2002022626A1 (en) 2002-03-21
JP2008195740A (ja) 2008-08-28
US6670344B2 (en) 2003-12-30
EP1320534A1 (en) 2003-06-25
NO20022270D0 (no) 2002-05-13
NO329973B1 (no) 2011-01-31
KR20020063187A (ko) 2002-08-01
ATE293630T1 (de) 2005-05-15
WO2002022626A8 (en) 2002-04-18
SK6722002A3 (en) 2002-11-06
NO20022270L (no) 2002-07-01
SK287117B6 (sk) 2009-12-07
IL149601A0 (en) 2002-11-10
AR030727A1 (es) 2003-09-03
EE200200249A (et) 2003-06-16
TWI250163B (en) 2006-03-01
EP1320534B1 (en) 2005-04-20
CN1392876A (zh) 2003-01-22
DE60110249T2 (de) 2006-03-02
CA2422359A1 (en) 2002-03-21
HK1052356A1 (en) 2003-09-11
US6855702B2 (en) 2005-02-15
CN100338077C (zh) 2007-09-19
HUP0204423A3 (en) 2005-02-28
NZ524926A (en) 2004-10-29
AU9077101A (en) 2002-03-26
RS50309B (sr) 2009-09-08
YU34802A (sh) 2005-07-19
US20040054212A1 (en) 2004-03-18
MXPA03002209A (es) 2004-03-02
HUP0204423A2 (en) 2003-05-28
PT1320534E (pt) 2005-08-31
HU229055B1 (hu) 2013-07-29
US20020072507A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
UY26935A1 (es) Sales de monoamina y diamina orgánica, sales de monoaminoácido y diaminoácido, y sales de éster de monoaminoácido y diaminoácido de precusor de fosfato de combretastatina a-4 campo de la invención
PA8553001A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos.
HRP20100038T1 (hr) Farmaceutski vaginalni gel koji sadrži tenofovir
BRPI0717794B8 (pt) composto e composição farmacêutica de ácido 3-amino-1-propanosulfônico
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
GT199900215A (es) Formulaciones agroquimicas.
UY27516A1 (es) Bencimidazoles
ES2213732T3 (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
NO20063244L (no) Florfenikolprolegemiddel som har forbedret vannloselighet
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
CR6165A (es) Procedimientos e intermedios para preparar compuestos anticancerosos
AR039467A1 (es) Procedimiento para preparar gama-butirolactamas y gama-aminoacidos muy funcionalizados
HN2003000185A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso.
CL2009001758A1 (es) Procedimiento de sintesis de ivabradina; enantiomeros (r) y (s) del compuesto (3,4-dimetoxi-biciclo[4.2.0]octa-1,3,5-trien-7-il)nitrilo como intermediarios y procedimiento de preparacion de los mismos mediante resolucion optica.
AR024462A1 (es) Tabletas farmaceuticas
UY28879A1 (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
ES2184302T3 (es) Procedimiento para la preparacion del acido 1,4,7,10-tetraazaciclododecano-1,4,7-triacetico y derivados del mismo.
ATE394379T1 (de) 4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung
AR027050A1 (es) Bencimidazoles, su preparacion y su empleo como medicamentos
MX2010006995A (es) 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico.
PA8531601A1 (es) Nuevos heteroaromatos
ES2183786T3 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos, procedimiento para su preparacion y su empleo como medicamentos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150630